Lupus & antiphospholipid syndrome
Application of the 2023 American College of Rheumatology (ACR)/EULAR antiphospholipid syndrome classification criteria to patients fulfilling the 2006 revised Sapporo criteria
Authors' conclusion
In Korean patients with APS, the concordance rate between the 2023 ACR/EULAR criteria and the 2006 revised Sapporo criteria was high. The concordance rate was considerably lower when confined to patients with obstetric APS.
Study context
- Population
- Korean patients classified as having antiphospholipid syndrome (APS) by the 2006 revised Sapporo criteria
- Participants
- 126 patients
- Exposure
- 2023 ACR/EULAR APS classification criteria vs 2006 revised Sapporo criteria
- Outcome
- Concordance rate between the 2023 ACR/EULAR criteria and the 2006 revised Sapporo criteria
Main finding
As reported in the abstract
Fulfilment of 2023 ACR/EULAR criteria (concordance)
Patients with APS by 2023 ACR/EULAR criteria, of 126
107
Concordance rate
84.9%
Observational data: associations, not effects.
Further findings
Concordance rate by index event
- VTE
- 100%
- Arterial thrombosis
- 76.4%
- Obstetric events
- 45.5%
- Lowest in obstetric events, attributable to the stricter obstetric criterion in the 2023 ACR/EULAR criteria
Original publication
Application of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria to patients fulfilling the 2006 revised Sapporo criteria. Clin Exp Rheumatol. Published 17 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →